Status:
COMPLETED
MMF Influence on HCV Viral Evolution After Liver Transplantation
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
HCV Infection
Liver Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
Samples from a large clinical trial comparing three immunosuppression regimens, two of which contained MMF, are used to identify the HCV viral quasispecies behaviour after liver transplantation
Eligibility Criteria
Inclusion
- All patients enrolled into - An Open Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety Among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection
Exclusion
Key Trial Info
Start Date :
September 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00170131
Start Date
September 1 2002
End Date
July 1 2007
Last Update
May 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Scottsdale, Arizona, United States, 85259